Determining Tumor Mutation Burden Using the Oncomine Tumor Mutation Load Assay

Now available to view on-demand

In several cancer models, it was shown that tumor mutation burden may correlate with response to immune checkpoint blockade therapy. However, whole-exome sequencing of FFPE samples is not ideal for implementation in molecular pathology laboratories.

In this webinar, we will present how Ion Torrent Oncomine Tumor Mutation Load Assay can be used in a pathology laboratory to determine this emerging biomarker starting from limited FFPE material.

Learning objectives of the webinar:

Why tumor mutation load is an emerging biomarker for immune checkpoint therapy
How an NGS research target panel can be used to determine mutation load biomarker in a 2-day workflow
Discuss how you can easily implement on clinical research samples in your laboratory

Speaker:

José Carlos Machado, PhD
Group Coordinator, Genetic Dynamics of Cancer cells at i3S
Associate Professor, Department of Pathology Medical Faculty of Porto

Fill in the form to view the free on-demand webinar.

(*Indicates a mandatory field)

First name*

Last name*

Name of Institution*

Telephone*

City*

Country/Region*

Email*

Would you like to request a quote for the Oncomine Mutation Load Assay?

Yes

Do you want a Thermo Fisher Scientific representative to speak to you about our NGS solutions for routine biomarker testing?

Yes